In addition, we are investing in leading players that fulfill the rapid growing needs in a nascent innovation driven eco-system in China. We are deeply involved in company building and hands-on to support strategy, operation, and development. Empowered by strong expertise in both science and business, our investment professionals are able to identify and nurture the next generation of great companies. We identify, incubate and invest in innovative early and growth stage companies globally and in China, with focus on:.
Shanghai, China
Founded in 2017
11-50 Employees
Working industry
Finance and Insurance
Type of company
-
Ownership structure
Privately Held
Locations
2 Locations
Number of products
16 Products
Specialised areas
Finance, Venture Capital
Quan Capital offers a wide range of products and services
Product
Leading Chinese specialty clinical development CRO that serves local and global biotech/pharma clients Archives | Quan Capital
Go to product >
Product
Innovative minimal invasive medtech for early-stage lung cancer treatment Archives | Quan Capital
Go to product >
Product
Global leader in circular RNA technology and therapies Archives | Quan Capital
Go to product >
Product
Clinical-stage biotech discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases Archives | Quan Capital
Go to product >
Product
Late clinical-stage biotech with an integrated platform for the development and commercialization of rare disease medicines in China Archives | Quan Capital
Go to product >
Product
Clinical stage biotechnology company developing breakthrough therapies based on GeneTAC™ platform to address diseases caused by genetic expansion Archives | Quan Capital
Go to product >
Product
Clinical-stage biotechnology company focusing on innovative therapeutics in ophthalmic diseases Archives | Quan Capital
Go to product >
Product
All exited Archives | Quan Capital
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
China
Overall risk estimation:
High
The ESG Data of countries are based on public sources
Environment
E
Grade (A-E)
View details
Social
C
Grade (A-E)
View details
Governance
E
Grade (A-E)
View details
Quan Capital operates in 2 countries around the world
Get an overview of the locations of Quan Capital
Location
Country
State
City
Headquarter
China
Shanghai
Shanghai
Boston office
United States
Massachusetts
Cambridge
Some frequent questions that have been asked about Quan Capital
Where is Quan Capital located?
The company headquarter of Quan Capital is located in Shanghai, Shanghai, China. Quan Capital has subsidiaries in United States
How many employees does Quan Capital approximately have?
As of the latest available information Quan Capital has around 11-50 employees worldwide.
When was Quan Capital founded?
Quan Capital was founded in 2017
In which industries does Quan Capital mainly work?
The company Quan Capital has it's main focus in the industries of Finance and Insurance
Check out some interesting alternative companies to Quan Capital
C2 Capital Partners
Hong Kong Island, China
11-50 Employees
2018
We provide growth capital, proprietary insights, and operational support to scale in China. We are committed to making a positive impact through our investments. Our team combines industry-leading expertise in e-commerce, FMCG, investment banking, management consulting, and private equity.
CM Venture Capital
Shanghai, China
11-50 Employees
2010
We’ve been experts in Chinese tech investments since 2010. Our multinational founders – American, French & Chinese – are fully qualified scientists. Our scientific background, coupled with economic sensibility, make for sound judgment in understanding how to commercialize innovation. While we are headquartered in Shanghai, China, our diverse portfolio remains global: from Asia, to North America, to Europe. Our growing portfolio of hard tech startups is constantly making an impact on industries ranging from 5G, healthcare, hydrogen energy, electronics, factories and more.
Pivotal bioVenture Partners
San Francisco, United States
1-10 Employees
2017
Established in 2017, we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe. We specialize in venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. We focus on capturing investment opportunities with publicly traded life sciences companies that are looking to scale and grow.
Nan Fung Life Sciences
San Francisco, United States
1-10 Employees
2017
Established in 2017, we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe. We specialize in venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. We focus on capturing investment opportunities with publicly traded life sciences companies that are looking to scale and grow.
Jebsen Capital
Hong Kong Island, China
11-50 Employees
-
Our thesis is centered around investing in category-defining companies that bring new products, services and experiences to the changing consumer in Greater China. We put our own capital behind entrepreneurs we believe in, which enables us to be long-term partners, not bound by fund lifecycles. As a strategic co-pilot to entrepreneurs and management teams, we offer a selection of tangible value creation solutions, together with our more than 2,000 employees in the region. Leading pet food and supplies retailer in Hong Kong. Leading online pet food and supplies business in Hong Kong.
Scala Ventures
Lugano, Switzerland
1-10 Employees
-
We help building outstanding companies with innovative technologies to offer unique service propositions. Due to our deep market and product knowledge we are able to identify future winners at an early stage and help them to achieve their ambitious targets.The main investment focus is on US / European company and product partnerships as these mature and leading markets provide higher upside and better risk control to maximize the value for all stakeholders.
